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Abstract
Aim Patient-reported outcome (PRO) measures (PROMs)
are standard measures in the assessment of colorectal can-
cer (CRC) treatment, but the range and complexity of
available PROMs may be hindering the synthesis of evi-
dence. This systematic review aimed to: (i) summarize
PROMs in studies of CRC surgery and (ii) categorize PRO
content to inform the future development of an agreed
minimum ‘core’ outcome set to be measured in all trials.
Method All PROMs were identified from a systematic
review of prospective CRC surgical studies. The type and
frequency of PROMs in each study were summarized,
and the number of items documented. All items were
extracted and independently categorized by content by
two researchers into ‘health domains’, and discrepancies
were discussed with a patient and expert. Domain popu-
larity and the distribution of items were summarized.
Results Fifty-eight different PROMs were identified
from the 104 included studies. There were 23 generic,
four cancer-specific, 11 disease-specific and 16 symp-
tom-specific questionnaires, and three ad hoc measures.
The most frequently used PROM was the EORTC
QLQ-C30 (50 studies), and most PROMs (n = 40,
69%) were used in only one study. Detailed examination
of the 50 available measures identified 917 items, which
were categorized into 51 domains. The domains com-
prising the most items were ‘anxiety’ (n = 85, 9.2%),
‘fatigue’ (n = 67, 7.3%) and ‘physical function’ (n = 63,
6.9%). No domains were included in all PROMs.
Conclusion There is major heterogeneity of PRO mea-
surement and a wide variation in content assessed in the
PROMs available for CRC. A core outcome set will
improve PRO outcome measurement and reporting in
CRC trials.
Keywords Colorectal cancer, surgery, patient-reported
outcomes, core outcome set, systematic review
Introduction
The measurement of patient-reported outcomes (PROs)
has become standard in the assessment of colorectal can-
cer (CRC) treatments, and their use is recommended by
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funding and regulatory agencies [1]. Many patient-
reported outcome measures (PROMs) have therefore
been developed for a variety of purposes [2]. Some are
generic, and allow comparisons between patients with
other conditions (e.g. SF-36, EQ-5D), others are
designed for patients with cancer (e.g. EORTC QLQ-
C30, FACT-G), and some are specific for CRC (e.g.
EORTC-CR29, FACT-C). To add further complexity,
each of these PROMs typically consists of a number of
questions (items), which are often grouped together to
represent similar concepts (scales). For example, two
questions regarding activities of daily living and leisure
activities in the EORTC QLQ-C30 measure are grouped
into a single ‘role function’ scale. There are therefore a
multitude of ways to measure PROs to evaluate treatment
for CRC, and this creates problems that may influence
the conduct and clinical impact of trials.
Trials may use different PROMs [3,4] making it
impossible to synthesize data across trials or undertake
meta-analyses. The multiplicity of results available from
trials means that it is difficult to interpret findings in the
context of clinical practice because of a lack of familiarity
with the number of measures, scales and items [2]. For
example, the scale ‘physical function’ exists in several dif-
ferent PROMs, but individual items in these scales vary
considerably between questionnaires. This is confusing
for clinicians, who may not be aware of the differences
between PROMs, and it is likely to limit the meaningful
use of the data in practice. Finally, the opportunities for
measuring multiple outcomes may lead to selective
reporting of significant findings. This can generate bias
and influence clinical interpretation of trials [5].
A proposed solution to these issues are ‘core out-
come sets’. Core outcomes are the minimum set of out-
comes that patients and professionals agree should be
measured in all trials of a certain condition [6]. They
aim to facilitate comparisons between trials and aid
meta-analysis by standardizing outcome measurement,
including PROs. The use of core sets may also facilitate
the clinical communication of data. Many core outcome
sets have now been developed in different clinical areas,
including rheumatology [7], paediatrics [8] and obstet-
rics [9], but not in CRC surgery. This systematic review
aims to examine the measurement of PROs in CRC
surgical studies, and use the data to inform the develop-
ment of the core outcome set.
Method
A systematic review of prospective CRC surgical studies
measuring PROs was undertaken to: (i) summarize
PRO measurement in CRC surgical studies, and (ii)
examine each PROM in detail and categorize analogous
concepts into domains to inform the future develop-
ment of a core outcome set.
Systematic search and data extraction
This systematic review adhered to a predefined protocol
(available on request from the authors). Validated terms
Table 1 OvidSP version of Medline search strategy.
Search criteria Search terms
Colorectal cancer 1. exp Colonic Neoplasms/
2. exp Rectal Neoplasms/
3. ((colorect$ or colon or colonic or
rect$) adj3 (cancer$ or tumo?r$ or
neoplasm$ or carcinoma$ or
adenocarcinoma$ or malignan$)).tw.
4. or/1-3
Surgery 1. exp Specialties, Surgical/
2. surg$.tw.
3. operat$.tw.
4. intervention$.tw.
5. procedur$.tw.
6. resect$.tw.
7. or/1-6
Randomized
controlled trials/
prospective studies
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trials.sh.
4. random allocation.sh.
5. double blind method.sh.
6. single-blind method.sh.
7. or/1-6
8. exp animals/not human/
9. 7 not 8
10. clinical trial.pt.
11. exp clinical trials/
12. (clin$ adj25 trial$).ti,ab.
13. ((singl$ or doubl$ or trebl$ or
tripl$) adj25 (blind$ or mask$)).ti,ab.
14. placebos.sh.
15. placebo$.ti,ab.
16. random$.ti,ab.
17. research design.sh.
18. or/10-17
19. 18 not 8
20. 19 not 9
21. comparative study.sh.
22. exp evaluation studies/
23. follow up studies.sh.
24. prospective studies.sh.
25. (control$ or prospective$ or
volunteer$).ti,ab.
26. or/21-25
27. 26 not 8
28. 27 not (9 or 20)
29. 9 or 20 or 28
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relating to ‘surgery’, ‘colorectal cancer’ and ‘prospective
studies’ (Table 1) were used to search the OVID SP
versions of MEDLINE, EMBASE and the Cochrane
Central Register of Controlled Trials. A validated filter
for ‘prospective studies’ was used because PRO data are
typically collected prospectively. The search was limited
to studies conducted in humans aged 18 years and over,
reported in the English language between January 2009
and December 2010. Previous reviews have considered
PROs of CRC surgery in terms of elderly patients [10],
methodological challenges in measuring PROs in CRC
[11], laparoscopic surgery [12], long-term survivors
[13], rectal cancer [3] and CRC before 2009 [14]. The
studies identified in these reviews were included. All
citations were collated with REFERENCE MANAGER 12
(Thomson Reuters, New York city, New York, USA)
and the duplicates removed.
Titles and abstracts of identified publications were
screened by one researcher. If there was uncertainty
about the eligibility of a publication the full paper was
also accessed. Articles were included if they were origi-
nal research papers reporting PROs of CRC surgery
(curative or palliative), with or without neoadjuvant or
adjuvant therapies, or systematic reviews of such publi-
cations. PROs were defined as end-points provided by
patients themselves and not interpreted by observers.
Studies of nonbiomedical interventions (e.g. alternative
medicine), palliative treatments that did not include a
surgical component (e.g. palliative chemotherapy),
screening studies, treatment of colorectal metastases and
molecular and genetic prognostic studies were all
excluded. Studies of more than one cancer site or of
mixed benign and malignant disease were included pro-
vided the data for CRC patients was presented sepa-
rately from that of the other diseases.
Data extraction included: participant demographics
(number, age and gender); treatment received (surgery,
neoadjuvant radiotherapy/chemoradiation and adjuvant
chemotherapy); treatment intent (curative or palliative);
the study design (randomized trial, case–control study,
cohort study, cross-sectional study, prospective case ser-
ies or other design); the PRO questionnaire used; and
the individual items included in each questionnaire.
When the individual questionnaires were not available
in publications, internet searches and direct contact with
authors were used to obtain the information. All data
were entered into a Microsoft Access (Microsoft, Red-
mond, Washington, USA) database to facilitate data
management and analyses. The data extraction was
checked by a second reviewer (ROF) for a sample of
included articles (n = 25) and any disagreements were
discussed and resolved with the senior author (JMB).
Initial search results
(n = 5644)
Duplicates removed
(n = 2127)
Excluded after abstract review
(n = 3196)
Full papers included
(n = 102)
Nonrandomized studies
(n = 77)
RCTs
(n = 25)
Excluded after full paper review
(n = 291)
De-duplicated results
(n = 3517)
Full papers accessed
(n = 321)
Included from other reviews
(n = 72)
Figure 1 PRISMA (Preferred Reporting
Items for Systematic Reviews) diagram of
studies considered for the systematic
review.
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Summary of PRO measurement in CRC surgery
The number of publications reporting each PROM
was tabulated and descriptive statistics used to sum-
marize PRO measurement. The popularity of PROMs
was assessed by comparing their frequency of use in
studies. A summary of each PROM is provided in
terms of the numbers of items, scales and whether a
total score was used. The distribution of items among
PROMs was examined by calculating the median
number and range of items per PROM. Question-
naires were categorized as: (i) generic (for use in all
patients), (ii) cancer specific (for use in all cancer
patients), (iii) CRC specific (for use in CRC patients),
(iv) symptom specific (to assess a single symptom,
e.g. pain), or (v) ad hoc.
Examination of PROs and domain categorization
Individual items from all questionnaires were extracted
and formed into a long-list before categorization into
health domains by two researchers (RNW and JR).
Both were kept masked as to which PRO questionnaire
the items were derived from. Two patient representa-
tives (JEJ and GS) and one consultant colorectal sur-
geon (AMP) subsequently checked this process.
Discrepancies were discussed and resolved with the
senior author (JMB).
Table 2 Summary of included articles.
All studies
(n = 102)
Randomized trials
(n = 25)
Nonrandomized
studies (n = 77)
Number of participants 66 386 7172 59 214
Age range of participants (years) 18–99 29–89 18–99
Number of participating centres (%)
Single 58 (57) 13 (52) 45 (58)
Multiple 44 (43) 12 (48) 32 (42)
IRB or ethical approval reported (%) 52 (51) 14 (56) 38 (49)
Tumour site (%)
Colon 10 (9) 2 (8) 7 (9)
Rectum 54 (53) 11 (44) 44 (55)
Mixed colon and rectum 38 (38) 12 (48) 26 (34)
Surgical approach (%)
Laparoscopy 1 (1) 0 1 (1)
Hand-assisted laparoscopy 0 0 0
Open 5 (5) 1 (4) 4 (5)
Mixed 13 (12) 9 (36) 5 (6)
Not reported or incomplete information reported 83 (81) 15 (60) 67 (87)
Neoadjuvant treatment* (%)
Radiotherapy alone 20 (20) 9 (36) 11 (14)
Chemotherapy alone 0 0 0v (0.0)
Chemoradiotherapy 22 (22) 3 (12) 18 (24)
None 7 (7) 1 (4) 6 (8)
Not reported or incomplete information reported 53 (51) 12 (48) 42 (54)
Adjuvant treatment* (%)
Chemotherapy or chemoradiotherapy 56 (55) 16 (64) 40 (52)
None 0 0 0
Not reported or incomplete information reported 46 (45) 9 (36) 37 (48)
Number of PROMs reported
1 43 10 33
2 47 12 35
3 6 2 4
4 4 1 3
5 2 0 2
IRB, Institutional Review Board.
*Some studies included patients with or without neoadjuvant therapy, some patients underwent different neoadjuvant or adjuvant
treatment within the same study.
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Table 3 Summary of identified patient-reported outcome measures (questionnaires) (n = 58).
Number
of items
Number
of scales
Overall
score
Frequency
(n = 184)
Name of generic questionnaire (n = 23)
Short Form-36 36 8 No 21
EuroQol-5D 6 6 Yes 3
Rotterdam Symptom Checklist 35 4 No 3
Gastrointestinal Quality of Life Index 36 0 Yes 2
Functional Difficulty Index 15 0 Yes 2
Illness Impact Scale 9 0 Yes 2
Visual Analogue Scale (overall health) 1 0 Yes 2
Self-rated health* – – – 1
Freiburger Illness Coping Strategies questionnaire* – – – 1
Brief Symptom Inventory-18 18 3 Yes 1
Constructed Meaning Scale 8 0 Yes 1
Surgical Recovery Score 31 0 Yes 1
Nottingham Health Profile 45 6 Yes 1
Duke Generic Instrument 17 11 Yes 1
Instrumental Activities of Daily Living 7 0 Yes 1
Profile of Moods States 65 6 Yes 1
Health and Activities Limitation Index 8 2 Yes 1
Health Utility Index 7 7 Yes 1
Spitzer Quality of Life Index 5 5 Yes 1
Global Quality of Life* – – – 1
Multidimensional Functional Assessment Questionnaire* – – – 1
Symptom Experience Scale 24 6 Yes 1
Ad hoc satisfaction questionnaire† 6 6 Yes 1
Name of cancer-specific questionnaire (n = 4)
EORTC QLQ-C30 30 15 No 50
Cancer-related Health Worries Scale 4 0 Yes 2
Quality of Life – Cancer Survivors 41 4 No 1
Cancer Problems in Living Scale 31 0 Yes 1
Name of disease-specific questionnaire (n = 11)
EORTC QLQ-CR38 38 9 No 33
Functional Assessment of Cancer Therapy – Colorectal 37 5 Yes 5
Modified City of Hope Quality of Life – Ostomy 41 6 Yes 2
EORTC QLQ-CR29 34 4 No 1
University of Padova Bowel Function Questionnaire 8 0 Yes 1
Bowel Function Questionnaire 8 0 Yes 1
Bowel Problems Scale 7 7 No 1
Late Effects Normal Tissue – subjective, objective, management, analytic scale* – – – 1
Quality of Life Index for Colostomy Patients 23 3 No 1
Colorectal Cancer Quality of Life 62 4 Yes 1
COloREctal Functional Outcome Questionnaire 26 5 Yes 1
Name of symptom-specific questionnaire (n = 17)
International Index of Erectile Function 15 5 Yes 4
Faecal Incontinence Quality of Life Questionnaire 29 4 No 3
Wexner Incontinence Scale 5 0 Yes 3
Visual Analogue Scale (pain) 1 0 Yes 3
Center for Epidemiologic Studies – Depression 20 6 Yes 3
Hospital Anxiety and Depression Scale 14 0 Yes 2
Holschneider Questionnaire 8 0 Yes 1
Internation Index of Erectile Function-5 5 5 Yes 1
Body Image Questionnaire 10 2 No 1
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Categorization was summarized using descriptive sta-
tistics to explore the distribution of items and PROMs
between domains. The number of items included in
each domain was counted, as were the number of
PROMs from which they were sourced. The contribu-
tion of each source PROM was demonstrated by calcu-
lating the median number and range of items included
from the measures.
Results
A total of 5644 titles and abstracts were identified, of
which 2127 were duplicates. The remaining 3517 were
screened and 29 original research articles included. In
addition to this, six systematic reviews of PROs in CRC
surgery identified a further 72 original research articles
(Fig. 1). In total, 102 original publications including
25 randomized controlled trials (25%) and 77 nonran-
domized studies (75%) reporting the outcome for
66 386 patients with CRC [15–116] were included.
The studies are summarized in Table 2.
Summary of PROM in CRC surgery
Fifty-eight different PRO questionnaires were identified
and these were reported 184 times in the included pub-
lications (Table 3). There were 23 (39.7%) generic
questionnaires, four (6.9%) cancer-specific question-
naires, 11 (19.0%) CRC-specific questionnaires and 17
(29.3%) symptom-specific questionnaires. Three ad hoc
questionnaires (those devised specifically for the study)
were not categorized.
Most questionnaires were reported only once
(n = 40, 69.0%). The most frequently reported were
the European Organisation for the Research and Treat-
ment of Cancer (EORTC) QLQ-C30 (50 studies,
48%), the EORTC QLQ-CR38 (33 studies, 32%) and
the Medical Outcome Study Short Form-36 (21 stud-
ies, 21%). The median number of items per PROM was
14, ranging from one [five PROMs: Visual Analogue
Scale (overall, pain and wound satisfaction), Satisfaction
with Sexual Function, and Present Pain Intensity
Index)] to 65 (the Profile of Mood States). Some 159
scales were evident, and most PROMs (n = 48, 83%)
included a total score.
Examination of PROs and domain categorization
Fifty (86.2%) full questionnaires were available. Reasons
for unavailability were inability to obtain the question-
naires from authors or web searches (n = 6) or lack of
an English language translation (n = 2). The 50 ques-
tionnaires comprised some 917 individual items, and
were categorized into 51 domains as described above
(Table 4). The full categorization is presented in Table
S1. The domains comprising the most items were ‘anxi-
ety’ (n = 85, 9.2%), ‘fatigue’ (n = 67, 7.2%) and ‘physi-
cal function’ (n = 63, 6.8%). The disease-specific
domains comprising most items were ‘faecal inconti-
nence’ (n = 53, 5.7%) and ‘stoma problems’ (n = 52,
5.6%). Most domains (n = 27, 53%) contained 10 or
more items.
There was little evidence of consistency between
PROMs. No domains were measured in all the PROMs.
Table 3 (Continued).
Number
of items
Number
of scales
Overall
score
Frequency
(n = 184)
Body Image Scale 10 0 Yes 1
Faecal Incontinence Scoring System 5 0 Yes 1
Patient Assessment of Constipation Symptom Scale 12 3 Yes 1
Present Pain Intensity Index 1 0 Yes 1
Satisfaction with Sexual Function 1 0 Yes 1
Visual Analogue Scale (wound satisfaction) 1 0 Yes 1
Symptom Distress Scale 15 0 Yes 1
Multidimensional Fatigue Inventory-20 20 5 No 1
Name of questionnaire (n = 3)
Ad hoc QOL questionnaire A*† – – – 1
Ad hoc QOL questionnaire B*† – – – 1
Ad hoc QOL questionnaire C*† – – – 1
EORTC, European Organisation for Research and Treatment of Cancer; QOL, quality of life.
*Questionnaire not available.
†PROM not validated.
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Table 4 Summary of domain categorization including number of items per domain, numbers of PROMs and median items per
PROM.
PRO domain (n = 51)
Number of items
(n = 917 (%)
Number of PROMs
(n = 50) (%)
Median items per source
PROM (range)
Psychological domains
Anxiety 85 (9.2) 22 (44) 2.5 (1–12)
Fatigue 67 (7.2) 21 (42) 1.0 (1–23)
Depression 47 (5.1) 16 (32) 1.5 (1–12)
Body image 37 (4.0) 13 (26) 1.0 (1–10)
Frustration/irritability 15 (1.6) 7 (14) 1.0 (1–9)
Outlook on life 13 (1.4) 5 (10) 2.0 (1–6)
Self-esteem 11 (1.2) 6 (12) 2.0 (1–3)
Coping 10 (1.1) 6 (12) 1.0 (1–3)
Spiritual 7 (0.7) 2 (4) 3.5 (3–4)
Regret 5 (0.5) 2 (4) 2.5 (1–4)
Control 3 (0.3) 3 (6) 1.0 (1)
Functional domains
Physical function 63 (6.8) 19 (38) 1.0 (1–9)
Role function 51 (5.5) 20 (40) 2.0 (1–7)
Social function 50 (5.4) 22 (44) 2.0 (1–8)
Sexual function 44 (4.7) 13 (26) 1.0 (1–15)
Cognitive function 30 (3.2) 14 (28) 1.0 (1–7)
Symptom domains
Faecal incontinence 53 (5.7) 12 (24) 2.0 (1–27)
Stoma problems 52 (5.6) 5 (10) 7.0 (7–21)
Pain 50 (5.4) 18 (36) 1.5 (1–8)
Insomnia 18 (1.9) 13 (26) 1.0 (1–4)
Appetite/eating problems 17 (1.8) 10 (20) 1.5 (1–3)
Faecal frequency 14 (1.5) 8 (16) 2.0 (1–3)
Nausea/vomiting 12 (1.3) 8 (16) 1.0 (1–3)
Faecal Urgency 11 (1.2) 8 (16) 1.0 (1–2)
Flatulence or gas 11 (1.2) 7 (14) 1.0 (1–3)
Treatment problems 11 (1.2) 7 (14) 1.0 (1–3)
Rectal blood or mucus 10 (1.1) 8 (16) 1.0 (1–2)
Bloating 7 (0.7) 6 (12) 1.0 (1–2)
Diarrhoea 7 (0.7) 7 (14) 1.0 (1)
Tenesmus 7 (0.7) 4 (8) 2.0 (1–2)
Constipation 6 (0.6) 5 (10) 1.0 (1–2)
Shortness of breath 5 (0.5) 5 (10) 1.0 (1)
Urinary frequency 5 (0.5) 3 (6) 2.0 (1–2)
Faint or dizzy 4 (0.4) 4 (8) 1.0 (1)
Hair problems 4 (0.4) 4 (8) 1.0 (1)
Discrimination 3 (0.3) 3 (6) 1.0 (1)
Dry mouth 3 (0.3) 3 (6) 1.0 (1)
Menstruation 3 (0.3) 3 (6) 1.0 (1)
Taste 3 (0.3) 3 (6) 1.0 (1)
Duration of bowel movement 2 (0.2) 2 (4) 1.0 (1)
Dyspepsia 2 (0.2) 2 (4) 1.0 (1)
Dysphagia 2 (0.2) 1 (2) 2.0 (2)
Dysuria 1 (0.1) 1 (2) 1.0 (1)
Urinary incontinence 1 (0.1) 1 (2) 1.0 (1)
Global domains
Global quality of life 12 (1.3) 9 (18) 1.0 (1–2)
Self-care 10 (1.1) 10 (20) 1.0 (1)
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The two domains that were best represented were ‘anxi-
ety’ and ‘social function’, each measured by 22 (44%)
PROMs. Otherwise, most domains (n = 39, 76%) were
measured by less than a quarter of PROMs, highlight-
ing further heterogeneity. There were two domains with
a high median number of items included per PROM:
‘stoma problems’, which contained 52 items from only
five PROMs (median seven items per PROM) and ‘sat-
isfaction with care’, which featured six items from just
one PROM. This may reflect specialization of PROMs,
with some measures focusing on very specific concepts.
Discussion
This systematic review aimed to summarize PRO mea-
surement in current CRC surgical studies and catego-
rize PRO items into analogous concepts to inform the
development of a core outcome set. There was evidence
of significant heterogeneity of PRO measurement in the
included studies. Fifty-eight different PROMs were used
to assess patient experience of colorectal surgery. Most
(n = 40, 69.0%) were only ever used once, and even the
most common (EORTC QLQ-C30) was measured in
less than half of the studies. PROMs also varied greatly
in terms of their content, with some as simple as a sin-
gle item while others included up to 65. Most (52%)
PROMs were not designed to be specific to CRC sur-
gery or symptoms thereof, and although this may bring
benefits in terms of comparison between diseases they
may not be sensitive enough to issues that are of spe-
cific importance to patients with CRC. Over 900 indi-
vidual questionnaire items were evident from 50
PROMs, and through a rigorous process, these were
categorized into 51 ‘health domains’. This demon-
strated a further lack of consistency, with no domains
being measured in all the PROMs, and most health
domains only being measured by less than a quarter of
PROMs. All of this highlights potentially major ques-
tions for evidence synthesis and clinical interpretation of
results in studies of CRC surgery, and demonstrates the
need for a standardized core outcome set.
Other studies have highlighted the problem with
outcome heterogeneity for clinical and PRO data. A
recently published systematic review identified 194 stud-
ies of CRC surgery that measured 766 different clinical
outcomes, with no single outcome reported in all
[117]. Even considering a seemingly simple outcome
such as mortality, there were over 84 different ways in
which this was defined and measured. The same prob-
lem has been highlighted in studies of oesophageal can-
cer surgery [118], where a review of 122 articles
reported 210 unique complications and 10 different
measures of operative mortality, and breast reconstruc-
tion following mastectomy for cancer [119], which
identified 134 studies reporting 950 unique complica-
tions. Problems with the multiplicity of PRO measures
have also been described previously in oesophageal sur-
gery [120], but there is no evidence of this issue in tri-
als of CRC surgery.
This study is the largest systematic review of PROs
in CRC and was conducted with rigorous methodology,
but there are some limitations. The review covers pub-
lished CRC studies in English up until 2010. A more
exhaustive search over a more recent period of time, or
inclusion of unpublished data or non-English publica-
tions may have yielded further PROs, but all the most
commonly used PROs were captured by these inclusion
criteria and extending the review would have probably
only identified additional rare PROs. The categorization
process could be criticized as arbitrary, but efforts were
made to objectify the process. First, two researchers cat-
egorized the questionnaire items independently, each
blinded to the other. Second, categorization was
checked for face validity by a patient representative.
Finally, there has been full disclosure of the categoriza-
tion in this article to allow scientific scrutiny of the
process.
Having identified all the potential patient reported
health domains measured in CRC surgical studies, the
next phase of this research is to gain a consensus on
which outcomes it is essential to measure in all trials.
Recommended methods to achieve this have been
defined by the international Core Outcome Measure-
ment in Effectiveness Trials (COMET) group [6].
Domains will be combined with clinical outcomes gen-
erated from a previous systematic review [117] to create
Table 4 (Continued).
PRO domain (n = 51)
Number of items
(n = 917 (%)
Number of PROMs
(n = 50) (%)
Median items per source
PROM (range)
Financial 8 (0.9) 5 (10) 1.0 (1–4)
Satisfaction with care 6 (0.6) 1 (2) 6.0 (6)
Information needs 1 (0.1) 1 (2) 1.0 (1)
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an exhaustive long-list of all potential outcomes. Key
stakeholders, including patients and professionals, will
then consider the importance of these outcomes and
undertake a prioritization exercise called the Delphi
process. This will allow the outcomes of lesser impor-
tance to be discarded from the core set. Finally, when
the number of outcomes has been reduced, face-to-face
meeting will be conducted to allow for debate about
their relative merits before the final core set is agreed.
In conclusion, this systematic review of CRC surgery
demonstrated significant heterogeneity of PRO mea-
surement that may hinder comparisons between studies,
limit meta-analysis and allow outcome reporting bias. A
long-list of patient reported ‘health domains’ was gener-
ated using robust methodology to inform the develop-
ment of a core outcome set.
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